MedTrace Logo

Evaluating the Feasibility and Acceptability of Implementing a PrEP Program in PR-CoNCRA (San Juan, Puerto Rico)- Part B

NCT03120494 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2018-04-05

No results posted yet for this study

Summary

75 subjects at risk for HIV infection (25 high risk MSM and 50 sero-discordant couples) will be recruited. All subjects will receive Truvada for pre-exposure prophylaxis or PrEP, as well as routine medical evaluations during one year. Subjects will be managed according to CDC's guidelines on the management of PrEP as a tool for HIV prevention.

Conditions

Interventions

DRUG

Emtricitabine and Tenofovir

All subjects will be provided study drug for use daily for one year.

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Puerto Rico Community Network for Clinical Research on AIDS

    lead OTHER

Principal Investigators

  • Vivian M Tamayo-Agrait, MD · PR-CoNCRA

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-06-30
Completion
2019-11-30

Countries

  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03120494 on ClinicalTrials.gov